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Primary hepatic lymphoma is a rare disorder representing less than 1% of all extranodal lymphomas. Histological 
examination of a primary hepatic lymphoma usually reveals a diffuse large B-cell lymphoma; there have been few 
reports of primary hepatic mucosa-associated lymphoid tissue (MALT) lymphomas. A 67-year-old man was being 
treated for a duodenal ulcer; while receiving therapy for the ulcer, a liver mass was incidentally found on abdominal 
ultrasonography. The pathologic diagnosis of the hepatic mass was an extranodal marginal zone B-cell lymphoma of 
MALT. The patient underwent radiotherapy with a total of 4,140 cGy delivered. The patient achieved complete 
remission and has been followed for 6 years with no recurrence of the disease. This report reviews the case of a 
primary hepatic extranodal marginal zone B-cell lymphoma of MALT successfully treated by radiotherapy alone.
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INTRODUCTION
Most identified lymphomatous infiltrations of the liver are a 
result of secondary involvement of widespread non-Hodgkin’s 
lymphoma. According to the diagnostic criteria for a primary 
hepatic lymphoma (PHL), suggested by Caccamo et al.1) the 
lymphoma is confined to the liver with no evidence of 
lymphomatous involvement of the spleen, lymph nodes, bone 
marrow, or other lymphatic organs. PHL is very rare and there 
is no consensus on the best approach for management2). In 
Korea, 14 cases of PHL, have been reported since 19793-9). The 
most common diagnosis for a PHL is diffuse large B-cell 
lymphoma (DLBL)10, 11). In addition, there have been a few 
reports of primary hepatic mucosa-associated lymphoid tissue 
(MALT) lymphomas. Here we report a case of primary hepatic 
extranodal marginal zone B-cell lymphoma of MALT which was 
successfully treated with radiotherapy alone.
CASE REPORT
A 67-year-old man, who was undergoing treatment for a 
bleeding duodenal ulcer, was admitted to our hospital for 
evaluation of a liver mass incidentally found on abdominal 
ultrasonography. The patient had a past medical history of 
angina pectoris, drug induced hepatitis, myocardial infarction, 
congestive heart failure and old pulmonary tuberculosis. The 
family history was none contributory. The patient complained of 
general weakness, easy fatigability and anorexia. He had no 
complaints of abdominal pain, weight loss, fever or night 
sweats. The blood pressure was 125/90 mmHg, pulse rate 
90/min and body temperature 36℃. He appeared chronically ill 
and had an alert mental status. There was no tenderness on 
abdominal examination. Hepatomegaly of two fingers breadth 
was noted below the right costal margin; there was no ascites. 
His spleen and lymph nodes were not enlarged. Laboratory 
blood tests showed a hemoglobin of 12.8 g/dL, hematocrit 37%, 
The Korean Journal of Internal Medicine: Vol. 21, No. 2, June, 2006128
Figure 2. Medium power view showing dense sheet-like infiltration 
of small lymphoid cells (H&E stain, ×100).
Figure 3. Immunohistochemical staining for CD20 showing diffuse 
membranous staining of the tumor cells (×200).
Figure 1. The initial liver MRI showing a 5.7×4.8 cm-sized well defined round solid mass 
(arrow) in the right lobe, segment 5 (T2 weighted axial images).
white blood cell 5,400/μL with 42.8% neutrophils, platelet count 
122,000/μL, blood urea nitrogen 14.2 mg/dL, creatinine 1.4 
mg/dL, total protein 7.8 g/dL, albumin 3.8 g/dL, total bilirubin 0.8 
mg/dL, alkaline phosphatase 53 IU/L, alanine aminotransferase 
(ALT) 30 IU/L, aspartate aminotransferase (AST) 35 IU/L, 
gamma glutamyl transferase (r-GT) 53 IU/L, lactate dehy-
drogenase (LDH) 250 IU/L (within normal range), prothrombin 
time 23 sec (98% of normal) and alpha-fetoprotein 3.5 ng/mL 
(within normal range). Hepatitis B surface antigen (HBsAg), 
antibody against hepatitis B surface antigen (anti-HBs) and 
antibody against hepatitis C (anti-HCV) were all negative. 
Abdominal magnetic resonance imaging (MRI) showed a well 
defined homogeneous mass 5.7×4.8 cm in size at segment 5 
(Figure 1). The following neck and chest computerized 
tomography (CT) scan showed no sign of other organ 
involvement or lymphadenopathy. Abdomen-pelvic CT scan 
showed no evidence of splenomegaly or lymphadenopathy. The 
whole body bone scan (WBBS) had no evidence of bone 
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Figure 4. Immunohistochemical staining for Ki-67 showing several 
scattered cells with positive nuclear Staining (×200).
Figure 5. Immunohistochemical staining for CD5 showing dense 
membranous staining of the scattered T-cell (×200).
Figure 6. Immunohistochemical staining for CD23 showing 
scattered aggregates of follicular dendritic cells (×100).
involvement. Gallium scan also showed no abnormal 
radioactivity. There were no malignant infiltrations noted on the 
bone marrow biopsy. Additional diagnostic evaluation included 
hepatic angiography and ultrasonograpy guided liver needle 
aspiration biopsy, using the gun shot approach, of the 
hypoechoic lesion in the right liver lobe. Hepatic angiography did 
not show any stained tumor, and lipiodol injection failed. Liver 
biopsy histology showed a severely distorted architecture due to 
lymphoreticular cell infiltration of the portal tract (Figure 2). The 
cells had the following features: they were uniform in size, had 
a slightly irregular outline and showed an increased nuclear- 
cytoplasmic ratio. They showed no particular arrangement 
representative of a specific organ. The cells expressed CD20 
(Figure 3) with a low Ki-67 labeling index supporting the 
diagnosis of a low grade tumor (Figure 4). The cells had no 
immunoreactivity for CD5 and CD23 (Figure 5, 6). The final 
pathologic diagnosis was an extranodal marginal zone B-cell 
lymphoma of MALT according to the WHO classification. The 
patient underwent radiotherapy with a total dose of 4,140 cGy 
(1,980 cGy on the entire liver and an additional 2,160 cGy 
focused on the tumor area).
Abdominal ultrasonography, performed 5 years after 
radiotherapy, revealed complete remission of the lymphoma in 
the liver. In addition, the liver MRI, studied 5 years after 
radiotherapy, showed fibrous contraction due to post radiation 
change of right lobe of the liver. There was no evidence of 
tumor recurrence in the liver parenchyma (Figure 7). However, 
a newly developed well-enhancing solid mass, highly suggestive 
of a malignancy, at the posterior basal segment of right lower 
lobe of lung, was incidentally discovered by MRI at this time.
Six years after diagnosis, he was readmitted due to 
complaints of dyspnea. The chest X-ray, chest CT scan and 
Whole body bone scan showed progression of the mass from 
the right lower lobe of the lung, pleural effusion, and multiple 
bone metastases. The patient refused additional diagnosis and 
treatment, and died as result of an undefined disease of the 
lung.
DISCUSSION
Primary hepatic lymphoma (PHL) is defined as a lymphoma 
localized and limited to the liver1). This type of tumor is very rare 
representing less than 1% of all extranodal non-Hodgkin’s 
lymphoma10, 11). In a review of 90 patients with PHL, conducted 
by Lei10) PHL was noted to occur primarily in middle-aged men 
(M:F=2.3:1); the most frequent presenting complaint was 
abdominal pain. The symptoms of fever and weight loss occur 
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Figure 7. The follow-up liver MRI (5 years after radiotherapy) showed fibrous contrst 
radiation changes in the right lobe of the liver. No evidence of tumor recurrence in the 
liver parenchyma (T2 weighted axial images).
in about one-third of the patients. Night sweats are less 
common and occur in about 10% of patients2, 10, 11). Objective 
findings on examination include hepatomegaly in at least 50% of 
patients, with icterus noted in only about 10～20%2). The 
etiology of PHL is unknown; however, several possible etiologic 
factors have been proposed. HCV or HBV infection is found in 
20～60% of patients with PHL2). The frequent association with 
HCV or HBV suggest that this virus may play a role in the 
pathogenesis of PHL. Our patient had no HCV or HBV 
infections. PHL may present radiologically as a solitary liver 
mass or as multiple lesions within the liver. The most common 
presentation is a solitary lesion, which occurs in about 55～60% 
of cases, followed by multiple lesions in about 35～40% of 
patients. Diffuse hepatic infiltration is rare and has a worse 
prognosis2). The predominant histology of the PHL is DLBL 
(46%); a few cases of MALT lymphoma, histiocytic, follicular, 
T-cell and others have also been described2, 10, 11). Hepato-
cellular carcinoma and metastasis from gastrointestinal (mostly 
colon) carcinoma are similar to PHL and are more common 
than. Normal levels of the tumor markers alpha-fetoprotein and 
carcinoembryonic antigen (CEA) are found in almost 100% of 
patients with PHL facilitating the differential diagnosis2, 10, 11). It is 
important to recognize that PHL may have a better prognosis 
than hepatocellular carcinoma or systemic disease that has 
secondarily affected the liver.
Since 1979 there have been 14 cases of PHL including 1 
case of MALT lymphoma in Korea3-9). The age of patients on 
admission ranged from 18 to 78 years (median age 41 years) 
with no male to female preponderance (M:F=1:1). DLBL was 
also the most frequent histologic type of PHL in Korea (36%)39).
Because this disorder is rare optimal management and 
treatment modalities for PHL are not yet well-established. 
Surgical treatment, radiotherapy and chemotherapy have all 
been reported as treatment modalities alone or in combination2) 
.Page et al. reported an excellent response rate associated with 
the use of multimodal chemotherapy alone (complete remission 
rate of 83.3%, 5-year relapse free survival rate of 83.1%)11). 
Contrary to Page et al. Scoazec et al. observed an inferior 
outcome in patients treated with chemotherapy alone compared 
to patients who were treated with surgery alone or 
chemotherapy plus radiotherapy modalities12). However, as Lei 
et al. pointed out, these discrepancies are attributable to patient 
selection. Chemotherapy is used mainly in patients who are not 
candidates for surgery or who had unresectable tumors, diffuse 
hepatic involvement, extrahepatic disease in the spleen or bone 
marrow, or high-grade histologic subtypes10). The prognosis for 
PHL may have been linked to the histologic subtypes, with short 
survival occurring in patients with unfavorable aggressive 
histologies2). Therefore, histologic subtypes and stage should be 
considered in the selection of the proper treatment modality for 
patients with PHL.
To our knowledge, there have only been two cases available 
Sang Yun Shin,et al: Longlasting Remission of Primary Hepatic MALT Lymphoma Achieved by Radiotherapy Alone 131
with information on the treatment and response for PHL of 
MALT type3, 13). A female patient with MALT lymphoma (3 cm 
diameter of mass) was treated by segmental resection alone 
and was alive and well 12 months after diagnosis3). Another 
female patient with a MALT lymphoma (4 cm diameter of mass) 
was treated surgically followed by localized radiotherapy and 
was alive and well free of disease 2.5 years after the 
diagnosis13). We chose radiotherapy for our patient with a 
primary hepatic MALT lymphoma (5.7 4.8 cm-sized mass) 
because of the low grade histologic subtype and localized 
disease. Our case had 5 years of disease free survival. The 
patient had undergone radiotherapy with a total dose of 4,140 
cGy and lived for 6 years. The doses of the radiotherapy used 
by Maes et al. were not reported13).
Previously, the primary therapeutic option for gastric MALT 
lymphoma was gastrectomy. As low-grade MALT lymphomas 
are very sensitive to radiation and respond well to lowdose 
radiation, radiotherapy is often used for the treatment of the 
gastric MALT lymphoma in order to preserve the stomach14). A 
recent report shows a 100% complete response rate with 
radiotherapy alone (median dose of 3,000 cGy) in 17 gastric 
MALT lymphoma patients15). Given the radiotherapy results for 
the gastric MALT lymphoma, radiotherapy alone may be a 
sufficient treatment modality for the treatment of primary hepatic 
MALT lymphoma. 
In conclusion, it is suggested that radiotherapy should be 
considered as the preferred treatment for localized primary 
hepatic extranodal marginal zone B-cell lymphoma of MALT.
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